Skip to main content

Table 2 Quantitatively assessments of implanted β-TCP using μ-CT

From: Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

  Group 1(Control) Group 2(rh-BMP-2) Group 3(ZOL) Group 4(rh-BMP-2 + ZOL) p value
BV/ TV (%, n = 7)
 3 weeks after implantation 21.7(17.8 to 27.1) 34.6(28.4 to 36.5) 24.3(20.2 to 28.5) 35.3(27.4 to 37.8) <0.001
 6 weeks after implantation 23.5(21.4 to 25.0) 22.8(20.0 to 25.1) 23.0(22.5 to 30.3) 30.4(27.0 to 33.9) <0.001
BMD (mgHA/ccm, n = 7)
 3 weeks after implantation 96.0(66.3 to 104.8) 161.5(101.2 to 201.1) 70.2(48.1 to 80.2) 170.4(102.2 to 178.2) <0.001
 6 weeks after implantation 35.4(17.7 to 60.0) 40.0(23.8 to 52.4) 57.9(43.7 to 74.4) 109.1(80.2 to 115.4) <0.001
  1. Median, minimum, and maximum are provided. P values indicate the statistical differences between the groups. Note: β-TCP Beta-tricalcium phosphate, rh-BMP-2 Recombinant human bone morphogenetic protein-2, ZOL Zoledronate.